NeoStem Inc (NYSEMKT:NBS) up by 2.42%, Incyte Corporation (NASDAQ:INCY)
NeoStem Inc (NYSEMKT:NBS) trading up by about 2.42% with a close of $0.585 on Tuesday. The beta of the stock is 0.70 which measures the company’s stock’s price volatility with respect to the index. The volume in the current trading session is close to 1.24 million, the relative volume of the stock which is the ratio of current volume and the three months average volume is 1.43. The insider ownership in the stock of NBS is about 4.08% and the institutional owners have increased their ownership over the past three months by about -0.89%. The profit margin of NBS is about -179.29% reflecting a poor performance by the company.
Progenitor Cell Therapy a subsidiary of NeoStem will now provide Provide Autologous and Allogeneic Cellular Therapy Services to MedStar Georgetown University Hospital.
Incyte Corporation (NASDAQ:INCY) shares closed at $24.49, trading up 2.51%. Incyte, a biopharmaceutical company focused on development of small molecule drugs for the treatment of serious medical needs, recently announced its first quarter results for the year 2013. The company reported $71.1 million in revenue for the quarter ended March 31, 2013, compared to $36.2 million for the same quarter previous year. While the net loss for the period was $15.7 million, or $0.12 earnings per share (EPS), as compared to $45.4 million net loss, or $0.36 EPS, for the same period in 2012. As of March 31, 2013, the company has total cash reserves of $270.2 million. Goldman Sachs has issued a “sell” rating on Incyte’s shares, and given a target price of $17.00 on the company’s stock. As of now, two research analysts have given a “sell” rating, one has issued a “hold” rating, and thirteen have issued a “buy” rating to the company.